{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:34:16Z","timestamp":1791995656454,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cgh.2024.07.010","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:12:17Z","timestamp":1722391937000},"page":"341-350.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod"],"prefix":"10.1016","volume":"23","author":[{"given":"Fernando","family":"Magro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-6409","authenticated-orcid":false,"given":"Diogo","family":"Branquinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Modesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2024.07.010_bib1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.07.010_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.07.010_bib3","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.07.010_bib4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.gie.2018.08.018","article-title":"The emerging role of histologic disease activity assessment in ulcerative colitis","volume":"88","author":"Pai","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cgh.2024.07.010_bib5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.010_bib6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cgh.2021.07.005","article-title":"Early change in epithelial neutrophilic infiltrate predicts long-term response to biologics in ulcerative colitis","volume":"20","author":"Narula","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.07.010_bib7","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1053\/j.gastro.2020.08.037","article-title":"Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis","volume":"159","author":"Li","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.07.010_bib8","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/ecco-jcc\/jjad050","article-title":"Resolving histological inflammation in ulcerative colitis with mirikizumab in the LUCENT induction and maintenance trial programmes","volume":"17","author":"Magro","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.010_bib9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ueg2.12288","article-title":"Ulcerative colitis: impact of early disease clearance on long-term outcomes - a multicenter cohort study","volume":"10","author":"D\u2019Amico","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2024.07.010_bib10","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2020.06.043","article-title":"Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis","volume":"159","author":"Yoon","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.07.010_bib11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/ibd\/izad159","article-title":"Disease clearance as a new outcome in ulcerative colitis: a systematic review and expert consensus","volume":"30","author":"D\u2019Amico","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.07.010_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41575-019-0211-1","article-title":"Evolving therapeutic goals in ulcerative colitis: towards disease clearance","volume":"17","author":"Danese","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.07.010_bib13","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.07.010_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12876-021-01650-7","article-title":"High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study","volume":"21","author":"Wilson","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cgh.2024.07.010_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MIB.0000000000000689","article-title":"Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn\u2019s disease and ulcerative colitis","volume":"22","author":"Yarur","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.07.010_bib16","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.cgh.2020.09.046","article-title":"Treat to target: the role of histologic healing in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"19","author":"Gupta","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.07.010_bib17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ecco-jcc\/jjac024","article-title":"The clinical significance of eosinophils in ulcerative colitis: a systematic review","volume":"16","author":"Mookhoek","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.010_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/ibd\/izad236","article-title":"Disease clearance is not synonymous with cure","volume":"30","author":"D\u2019Amico","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2024.07.010_bib19","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1093\/ecco-jcc\/jjab076.396","article-title":"P271 Evolving targets in ulcerative colitis: defining disease clearance in the VARSITY study","volume":"15","author":"Danese","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2024.07.010_bib20","doi-asserted-by":"crossref","first-page":"i529","DOI":"10.1093\/ecco-jcc\/jjac190.0528","article-title":"P398 Disease clearance: a potential target for management of patients with ulcerative colitis","volume":"17","author":"Andronic","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2024.07.010_bib21","doi-asserted-by":"crossref","first-page":"i110","DOI":"10.1093\/ecco-jcc\/jjac190.0083","article-title":"DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients","volume":"17","author":"Dignass","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.010_bib22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjac030","article-title":"Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension","volume":"16","author":"Abreu","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 8","key":"10.1016\/j.cgh.2024.07.010_bib23","article-title":"PO404 Association between absolute lymphocyte count and ozanimod efficacy and safety in patients with moderately to severely active ulcerative colitis: results from the phase 3 True North study","volume":"10","author":"Harris","year":"2022","journal-title":"United European Gastroenterol J"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524006815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524006815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T12:16:01Z","timestamp":1737634561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356524006815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1542356524006815"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2024.07.010","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2024.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}